36 patents
Utility
Interoperable platform for reducing redundancy in medical database management
16 Jan 24
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey Kim, Bobby Y. Reddy, Joel Choi Park, Rajuli Lall
Filed: 28 Mar 23
Utility
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
14 Nov 23
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei Wang, Yunhang Guo, Gongyin Shi
Filed: 6 Jul 22
Utility
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
17 Oct 23
Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody.
James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang
Filed: 29 Nov 18
Utility
Methods of treating B-cell proliferative disorder
17 Oct 23
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer.
Jason Paik, Tommi Salmi, Ying Ou
Filed: 19 Jan 23
Utility
Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
15 Aug 23
Jing Li, Haibo Zhao, Zhiwei Wang
Filed: 8 Jul 21
Utility
Treatment of B cell cancers using a combination comprising Btk inhibitors
18 Jul 23
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.
Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo
Filed: 18 Aug 17
Utility
Interoperable platform for reducing redundancy in medical database management
25 Apr 23
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey Kim, Bobby Y. Reddy, Joel Choi Park, Rajuli Lail
Filed: 31 May 22
Utility
Immunotherapy for hepatocellular carcinoma
7 Mar 23
Disclosed herein is method for the prevention, delay of progression or treatment of hepatocellular carcinoma in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of an anti-PD-1 antibody, which is an antibody or a fragment antigen binding thereof, specifically binding to human PD-1.
Lai Wang, Kang Li, Qinzhou Qi, Jeannie Hou, Zhong Wu
Filed: 26 Jun 18
Utility
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
28 Feb 23
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang
Filed: 10 May 22
Utility
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
17 Jan 23
Yunhang Guo, Desheng Yu, Zhiwei Wang
Filed: 25 Jan 18
Utility
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
27 Dec 22
Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy.
Jing Song, Lai Wang, Kang Li, Tong Zhang, Lusong Luo, Min Wei, Zhiyu Tang, Guoliang Zhang, Changyou Zhou
Filed: 16 Nov 20
Utility
Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
29 Nov 22
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
Kang Li, Jing Song, Tong Zhang, Yucheng Li, Zhiying Ren, Yanshen Kang
Filed: 5 Dec 19
Utility
Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
18 Oct 22
Disclosed herein are novel benzoimidazoles and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy.
Hexiang Wang, Yunhang Guo, Zhiwei Wang, Changyou Zhou
Filed: 24 Nov 18
Utility
Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
18 Oct 22
Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same.
Guoliang Zhang, Changyou Zhou
Filed: 8 Apr 19
Utility
Bcl-2 inhibitors
23 Aug 22
Yunhang Guo, Hai Xue, Zhiwei Wang, Hanzi Sun
Filed: 29 Apr 19
Utility
Interoperable platform for reducing redundancy in medical database management
19 Jul 22
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey Kim, Bobby Y. Reddy, Joel Choi Park, Rajuli Lall
Filed: 13 Jul 21
Utility
BTK inhibitors with improved dual selectivity
5 Jul 22
Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).
Zhiwei Wang, Yunhang Guo, Desheng Yu
Filed: 12 Aug 18
Utility
Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors
11 Jan 22
Jing Li, Haibo Zhao, Zhiwei Wang
Filed: 7 Sep 18
Utility
Anti-TIGIT antibodies and their use as therapeutics and diagnostics
4 Jan 22
Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells.
Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li
Filed: 29 Dec 18
Utility
Treatment cancers using a combination comprising PARP inhibitors
21 Dec 21
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent.
Lai Wang, Zhiyu Tang, Lusong Luo, Min Wei, Kang Li, Jing Song, Tong Zhang, Hexiang Wang, Bo Ren, Changyou Zhou
Filed: 27 Sep 17